Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) – 02

References

• NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95
   Google Scholar
• Oleksik A, Lips P, Dawson A, et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 2000;15:1384-92
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 1996;1535-41
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280: 2077-82
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282: 1344-52
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282: 637-45
   PubMed Web of Science ®Google Scholar
• Japanese Guideline for the Prevention and Treatment of Osteoporosis 2006 Edition [in Japanese]. Life Science Publishing, 2006
   Google Scholar
• Brown JP, Josse RG, for the Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167(10 Suppl.):S1-S34
   Google Scholar
• Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428
   PubMed Web of Science ®Google Scholar
• Hodgson SF, Watts NB, Bilezikian JP, et al.; AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003;9:544-64
   Google Scholar
• Body JJ, Bergmann P, Boonen S, et al. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int 2010;21:1657-80
   PubMed Web of Science ®Google Scholar
• Qaseem A, Snow V, Shekelle P, et al. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008;149:404-15
   PubMed Web of Science ®Google Scholar
• Watts NB, Lewiecki EM, Bonnick SL, et al. Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res 2009;24:1643-6
   PubMed Web of Science ®Google Scholar
• Dowd R, Recker RR, Heaney RP. Study subjects and ordinary patients. Osteoporos Int 2000;11:533-6
   PubMed Web of Science ®Google Scholar
• Nakamura K, saito T, Oyama M, et al. Vitamin D sufficiency is associated with low incidence of limb and vertebral fractures in community-dwelling elderly Japanese women: the Muramatsu Study. Osteoporosis Int 2011;1:97-103
   Google Scholar
• Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005;293:2257-64
   PubMed Web of Science ®Google Scholar
• Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med 2009;169:551-61
   PubMed Web of Science ®Google Scholar
• Ministry of Health, Labour, and Welfare, Japan. The National Nutrition Survey, 2003 [in Japanese]. Available at: http://www.mhlw.go.jp/houdou/2005/04/h0421-1.html
   Google Scholar
• Shiraki M, Ohta H, Hosoi T, et al. A-TOP study plan (3), survey of bisphosphonate [in Japanese]. Osteoporosis Jpn 2003;11:665-9
   Google Scholar
• Shiraki M, Kuroda T, Miyakawa N, et al. Design of a novel approach to evaluate the effectiveness of concurrent treatment for prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial (JOINT) initiated by the Research Group of Adequate Treatment of Osteoporosis (A-TOP). J Bone Miner Metab 2011;29:37-43
   PubMed Web of Science ®Google Scholar
• Orimo H, Hayashi Y, Fukunaga M, et al. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 2001;19:331-7
   PubMed Web of Science ®Google Scholar
• Nishizawa Y, Nakamura T, Ohta H, et al. Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis: Japan Osteoporosis Society. Guidelines on the use of biochemical markers of bone turnover in osteoporosis. J Bone Miner Metab 2001;19:338-44
   PubMed Web of Science ®Google Scholar
• Genant HK, Wu CY, van Kuijk C, et al. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137-48
   PubMed Web of Science ®Google Scholar
• Kushida K, Shiraki M, Nakamura T, et al. The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trial. Curr Therapeut Res 2002;63:606-20
   Web of Science ®Google Scholar
• Papadimitropoulos E, Wells G, Shea B, et al. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:560-9
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (1998) ICH Harmonized Tripartite Guideline: statistical principles for clinical trials. Available at http://www.ich.org/cache/compo/276-254-1.html [Last accessed 25 December 2009]
   Google Scholar
• Hagino H, Nakamura T, Fujiwara S, et al. Sequential change in quality of life for patients with incident clinical fractures: a prospective study. Osteoporos Int 2009;20:695-702
   PubMed Web of Science ®Google Scholar
• Dawson-Hughes B, Mithal A, Bonjour JP, et al. IOF position statement: vitamin D recommendations for older adults. Osteoporos Int 2010;21:1151-4
   PubMed Web of Science ®Google Scholar
• Boonen S, Rizzoli R, Meunier PJ, et al. The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: a consensus report. Osteoporos Int 2004;15:511-19
   PubMed Web of Science ®Google Scholar
• Lips P, Bouillon R, van Schoor NM, et al. Reducing fracture risk with calcium and vitamin D. Clin Endocrinol (Oxf) 2010;73:277-85
   PubMed Web of Science ®Google Scholar
• Uenishi K, Ishida H, Kamei A, et al. Calcium requirement estimated by balance study in elderly Japanese people. Osteoporos Int 2001;12:858-63
   PubMed Web of Science ®Google Scholar
• Riggs BL, Melton LJ 3rd. Involutional osteoporosis. N Engl J Med 1986;314:1676-86
   PubMed Web of Science ®Google Scholar
• Sakai A, Oshige T, Nakamura T, et al. Shorter unipedal standing time and lower bone mineral density in women with distal radius fractures. Osteoporosis Int 2010;21:733-9
   PubMed Web of Science ®Google Scholar
• Hagino H, Fujiwara S, Nakashima E, et al. Case–control study of risk factors for fractures of the distal radius and proximal humerus among the Japanese population. Osteoporosis Int 2004;15:226-30
   PubMed Web of Science ®Google Scholar
• Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003;33:522-32
   PubMed Web of Science ®Google Scholar
• Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-3
   PubMed Web of Science ®Google Scholar
• Gallagher JC, Genant HK, Crans GG, et al. Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 2005;90:1583-7
   PubMed Web of Science ®Google Scholar